Incyte Corporation (INCY)

77.19
+1.17(+1.54%)
After Hours
77.08
-0.11(-0.14%)
- Real-time Data
  • Volume:
    1,142,877
  • Day's Range:
    75.80 - 77.34
  • 52 wk Range:
    61.91 - 88.26

INCY Overview

Prev. Close
76.02
Day's Range
75.8-77.34
Revenue
3.11B
Open
76.45
52 wk Range
61.91-88.26
EPS
4.2
Volume
1,142,877
Market Cap
17.1B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,404,072
P/E Ratio
18.37
Beta
0.71
1-Year Change
-6.64%
Shares Outstanding
221,505,011
Next Earnings Date
Aug 02, 2022
What is your sentiment on Incyte?
or
Market is currently closed. Voting is open during market hours.

Incyte Corporation News

  • Incyte Earnings Beat, Revenue Misses In Q1
    • ByInvesting.com-

    Investing.com - Incyte (NASDAQ:INCY) reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Incyte announced...

  • Incyte Misses Q1 EPS by 14c
    • ByInvesting.com-

    Incyte (NASDAQ:INCY) reported Q1 EPS of $0.55, $0.14 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $728 million versus the consensus estimate of...

Incyte Corporation Analysis

Incyte Corporation Company Profile

Incyte Corporation Company Profile

Employees
1773

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyNeutral
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • To da moon
    1
    • not working for me
      2
      • antes Arias Santi Arias
        3
        • Google play Khmer🌟
          0
          • Why is this guy down?
            1
            • What is going on this stock? It has been dipping with no limit?!
              1
              • asc
                0
            • beat Earnings, why down?
              3
              • Turkish biotechnology company produces RTALB diagnostic kit. Its products are in demand in 15 countries. The company has exported more than 2 million kits in the past month.
                3
                • This is why the stock lost 44% for the year? Who said $175?
                  1
                  • goes to 50...hmm
                    1
                    • Papa Putin said so?
                      2